Kaftrio is a combination of drugs used to treat cystic fibrosis caused by the F508del mutation in the CFTR gene, which affects the respiratory, digestive, and reproductive systems. It was approved by the FDA in 2019 and improves lung function and reduces chronic respiratory infections by helping the CFTR protein work correctly. Clinical trials have shown up to 14% improvement in forced expiratory volume and reduced sweat chloride levels. Kaftrio has side effects but is generally well-tolerated. It has a high cost, but Vertex Pharmaceuticals is working to ensure access.